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Abstract
Background: The quaking homolog, KH domain RNA binding (mouse) (QKI) is a candidate gene for
schizophrenia. Disturbed QKI mRNA expression is observed in the prefrontal cortex of patients,
and some of these changes correlate to treatment with antipsychotic drugs.
To test if low doses of antipsychotic drugs can modify QKI mRNA expression, human astrocytoma
(U343) and oligodendroglioma (HOG) cell lines were treated with five different antipsychotic drugs
including Haloperidol, Aripiprazole, Clozapine, Olanzapine and Risperidone. Messenger RNA
expression levels of splice variants QKI-5, QKI-6 and QKI-7 were measured by Real-Time PCR.
Results: Haloperidol treatment (0.2 μM) doubled QKI-7 mRNA levels in U343 cells after 6 hours
(p-value < 0.02). The effect was dose dependent, and cells treated with ten times higher
concentration (2 μM) responded with a five-fold and three-fold increase in QKI-7, 6 and 24 hours
after treatment, respectively (p-values < 0.0001).
Conclusion: The results in U343 cells suggest that QKI-7 mRNA expression in human astrocytes
is induced by Haloperidol, at concentrations similar to plasma levels relevant to clinical treatment
of schizophrenia. The molecular mechanism of action of antipsychotic drugs after binding to
receptors is not well known. We hypothesize that QKI regulation is involved in this mechanism.
Background
QKI was recently proposed as a candidate gene for schizo-
phrenia based on linkage, association and mRNA expres-
sion studies [1-3]. The alteration of expression levels
involves differential expression of splice variants. An ear-
lier study showed decreased expression levels of QKI
splice variant seven (QKI-7) in frontal cortex of schizo-
phrenia patients [2]. QKI controls expression of oli-
godendrocyte related (OR) genes, as reviewed previously
[4], and expression of OR genes has clearly been shown to
be altered in schizophrenia [5]. Furthermore, QKI expres-
sion was recently shown to be both necessary and suffi-
cient to promote myelination of oligodendrocytes [6].
Astrocytes also play a role in myelination by mediating
communication between axons and myelinating glial
cells [7] and it has been suggested that these two cell types
are involved in the pathophysiology of schizophrenia. [8].
Interestingly, an association between the type of antipsy-
chotic drugs patients received and QKI mRNA expression
was shown previously [2]. We hypothesized that antipsy-
chotic medication influences QKI expression. To test this
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hypothesis we treated human oligodendroglioma (HOG)
and astrocytoma (U343) cell lines with five different
antipsychotic drugs, at levels similar to clinical plasma
concentrations [9-12]. We show that Haloperidol stimu-
lates QKI-7 mRNA expression selectively in U343 cells.
Results
To test whether antipsychotic drugs affect QKI mRNA
expression in U343 and HOG cells, we treated cell cul-
tures with Aripiprazole, Clozapine, Haloperidol, Olanza-
pine or Risperidone for 6 and 24 hours. In U343 cells, the
most significant change in mRNA expression levels was a
2.1-fold increase of QKI-7 (p-value < 0.02) after 6 hour
treatment with Haloperidol (Figure 1A–C and Additional
file 1, Table 2a). At this concentration the effect appeared
to be transient and expression levels in treated cells were
similar to those in control cells after 24 hours. A slight
decrease in mRNA expression was also detected for QKI-7
when the U343 cell line was treated with Risperidone or
Clozapine (Figure 1C and Additional file 1, Table 2a). In
HOG cells, we only observed a slight increase of QKI-6
mRNA levels (p-value 0.03) in response to Risperidone
(Figure 1D–F and Additional file 1, Table 2b). The
increase of QKI-6 in the oligodendroglioma cell line by
the atypical antipschotica Risperidone does not reflect
previous alterations observed in brains of patients [1-3].
However, it is important to remember that no patients are
treated exclusively by Risperidone. Furthermore, changes
detected in brain of patients are the result of drug effects
on multiple cellular pathways and cannot directly be com-
pared with in vitro effects on a single cell line. In any case,
our current in vitro experiments and the previous analysis
of post-mortem brains coincide in the suggestion of alter-
ations in QKI control in both astrocytes and oligodendro-
cytes after treatment with antypsychotic drugs
To further evaluate the effect of Haloperidol on QKI-7
mRNA expression, we treated U343 cells with 10 times
higher concentration (2 μM) and observed a five-fold
increase after 6 hours (p-value < 0.0001) and a three-fold
increase after 24 hours (p-value < 0.0001) (Figure 2 and
Additional file 1, Table 2c). Antipsychotic drugs are
known to bind to dopamine receptor 2 (D2R) and/or 3
(D3R) among other receptors. To evaluate whether
dopamine receptors were present in the cells we measured
mRNA levels of both receptors in each cell line. We
detected low levels of D2R mRNA expression in both
U343 and HOG cells (Figure 3). D3R expression was not
detected in either of the cell types (data not shown).
Discussion
A previous study showed that post-mortem samples from
schizophrenia patients had different mRNA levels of QKI
splice variants depending on the medication received by
the patients [2]. However, it was not evaluated whether
QKI alterations were due to a direct or indirect effect on
medication, and what cell type(s) were involved. In this
study, we show that treatment of a human astrocytoma
cell line with the typical antipsychotic agent Haloperidol
results in alterations of QKI expression levels. Further-
more, this change was observed using a concentration
similar to plasma levels detected in patients, suggesting
the possibility that Haloperidol affects astrocyte function.
The observed increase of QKI-7 mRNA expression is in
agreement with previous findings by Aberg et al., showing
increased gene expression of QKI in schizophrenic
patients treated with typical antipsychotic agents [1,2]. A
caveat to the interpretation to our results is that it is diffi-
cult to compare a transient increase of QKI-7 in astrocy-
toma cells with effects in vivo after chronic treatment of
patients with Haloperidol and other drugs. However, our
results indicate for the first time a link between Haloperi-
dol action and QKI control within astrocytoma cells.
These observations suggest a direct link between Haloperi-
dol and QKI control in astrocytes, and they clearly indi-
cate that the molecular pathway in which QKI is involved,
is affected during haloperidol action both in in vivo and in
vitro experiments.
Alteration of QKI expression after Haloperidol treatment
has also been shown in mice [13], but the direction of the
change was the opposite. The most reasonable explana-
tion to the differences between the studies is that Naryan
et al. worked with an in vivo model in mice whereas we
worked with an in vitro model in humans. Differences in
cell types between the species, as well as the absence of in
vitro models of neuronal circuits and inter-cellular rela-
tionships present in the living brain makes the results dif-
ficult to compare. In other words, Naryan et al showed an
effect of Haloperidol on QKI in mice neuronal networks
while our study shows the individual effect of Haloperi-
dol on glial cell lines. However, both studies coincide in a
relationship between Haloperidol and QKI pathways. The
molecular and cellular details of this interaction remain to
be elucidated.
Previous studies found that dopamine receptors were
expressed in primary astrocytic cultures [14]. We con-
firmed the expression of D2R in the U343 cells at the
mRNA level. In addition, D1R and D2R proteins were pre-
viously detected in human astrocytoma cell lines, as pub-
lished in the Human Protein Atlas http://
www.proteinatlas.org. It is therefore possible that the
increased expression of QKI-7 is mediated by Haloperidol
binding to D2R. However, drug action through binding to
other receptors cannot be excluded at this point. Future
binding studies will clarify this point. If antipsychotic
drugs affect QKI expression via binding to dopamine
receptors, it would be expected that all drugs used in this
study would affect QKI levels. However, this was not the
case and the most pronounced effect was observed withBMC Pharmacology 2009, 9:6 http://www.biomedcentral.com/1471-2210/9/6
Page 3 of 6
(page number not for citation purposes)
The graphs show the mean fold change of relative gene expression values of QKI splice variants (QKI5, QKI6 and QKI7) in  U343 (1A-C) and HOG cells (1D-F) treated with Aripiprazole (A), Clozapine (Cl), Haloperidol (H), Olanzapine (O) and Risp- eridone (R) Figure 1
The graphs show the mean fold change of relative gene expression values of QKI splice variants (QKI5, QKI6 
and QKI7) in U343 (1A-C) and HOG cells (1D-F) treated with Aripiprazole (A), Clozapine (Cl), Haloperidol 
(H), Olanzapine (O) and Risperidone (R). The bars for the control samples are indicated with a C. Error bars indicate 
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Haloperidol. This does not exclude the possibility of D2R
involvement since it is possible that Haloperidol may
occupy more D2R than other agents when low doses are
used.
Interestingly, when HOG cells were treated with Risperi-
done we observed a slight increase of QKI-6 mRNA levels.
In U343 cells we did not detect an effect on QKI-6.
Instead, we found a decrease of QKI-7 mRNA expression.
Risperidone appears to have different effect on QKI in
HOG cells and astrocytic cells, although the change in
gene expression was not as pronounced as when
Haloperidol was used.
Conclusion
In summary, our results suggest a direct effect of Haloperi-
dol treatment on QKI mRNA expression in astrocytes. A
smaller effect on QKI expression was also detected when
the cells were treated with Risperidone. The physiological
effect of these changes on the symptoms of the patients,
and the normal function of QKI in astrocytes and oli-
godendrocytes remain to be investigated. This knowledge
could contribute to understand the molecular mechanism
of action of antipsychotic drugs after binding to receptors,
and it may also help to find new and better drug targets for
the disease.
Methods
Treatment of cell lines
U343 and HOG cells were cultivated in Dulbecco's Modi-
fied Eagle Medium (DMEM, 61965-026, GIBCO™) sup-
plemented with 10% fetal bovine serum (FBS, 10270-106,
GIBCO™) and 1% penicillin-streptomycin solution
(PEST, 15140-122, GIBCO™). Although some of the char-
acteristics typical for oligodendrocytes and astrocytes may
be changed in the glioma cells they are used for these
experiments since it is not possible today to derive these
cell types from a living human brain to perform this
experiment. The cells were cultivated to about 30% con-
fluence before treatment with antipsychotic drugs.
Medium to treat the cells contained 1 μM Aripiprazole
(A771000, Toronto Research Chemicals Inc.), 2 μM Cloz-
apine (C6305, Sigma-Aldrich), 0.2 μM Haloperidol
(H1512, Sigma-Aldrich), 0.25 μM Olanzapine (O253750,
Toronto Research Chemicals Inc.) or 0.15 μM Risperidone
(R525000, Toronto Research Chemicals Inc.), respec-
tively, in DMEM supplemented with 10% FBS and 1%
PEST. The concentrations used were in the typical range of
blood plasma levels observed in patients treated with the
drugs [9-12]. Three biological replicates were done for
each test. The cells were treated for 6 or 24 hours. Control
cells that were not treated, were incubated with the same
medium without the antipsychotic agents, for 6 or 24 h.
The cells were harvested by adding Trizol (Life Technolo-
gies, Sweden) directly to the cell plate after removing the
The graph shows dose-response for Haloperidol concentra- tions 0 μM, 0.2 μM and 2 μM in treated U343 cells Figure 2
The graph shows dose-response for Haloperidol con-
centrations 0 μM, 0.2 μM and 2 μM in treated U343 
cells. The fold-change in quantity is plotted against the drug 
concentration, for 6 and 24 hours. Error bars indicate stand-
ard errors. The asterisks indicate significant results (*** indi-






























The graph shows the expression of the dopamine 2 receptor  in U343 and HOG cells Figure 3
The graph shows the expression of the dopamine 2 
receptor in U343 and HOG cells. ΔCT are derived by 
subtracting the CT values obtained from the Negative Ampli-
fication Control (samples where no enzyme was added to 
the reverse transcription) with the CT obtained from the 














 CTBMC Pharmacology 2009, 9:6 http://www.biomedcentral.com/1471-2210/9/6
Page 5 of 6
(page number not for citation purposes)
medium, and the samples were collected in eppendorf
tubes prior to RNA isolation.
In the initial experiment, we detected an increase of QKI-
7 mRNA expression in Haloperidol treated U343 cells. To
test whether the effect was dose dependent we performed
an additional treatment with this drug using 10 times
higher concentration (2 μM).
RNA isolation and Gene expression analysis
RNA was isolated according to standard Trizol extraction
procedures [15]. The concentration of RNA was measured
with a NanoDrop® ND-1000 Spectrophotometer (Nano-
Drop Technologies). RNA samples were stored at -70°C
prior to use.
Reverse transcription reactions included 1 μL RT-buffer
(10×), 2.2 μL MgCl2 (25 mM), 2 μL dNTPs (10 mM), 0.5
μL oligo dT (10 μg/L), 0.2 μL RNase inhibitor, 0.25 μL
reverse transcriptase (Taqman Reverse Transcription Rea-
gents, N808-0234, Applied Biosystem) and 3.85 μL of
sample (about 500 ng of RNA). These reactions were incu-
bated at 25°C for 10 min and 48°C for 1 hour.
Real-time RT-PCR was performed with an ABI PRISM
7000 Sequence Detection System (Applied Biosystems,
Foster City, USA) as follows: 2 minutes at 50°C and 10
minutes at 95°C followed by 40 cycles of 15 seconds at
95°C and 1 minute at 60°C. Each reaction was carried out
in a total volume of 25 μL, consisting of 9.8 μL Power
SYBR® PCR Master mix (Applied Biosystems, Foster City,
USA), 0.3 μM of each primer (Thermo Electron Coopera-
tion, Germany) and ~10–100 ng of cDNA. The primer for
the reference gene (actin-β, ACTB) as well as for the QKI
splice variants, QKI-5, QKI-6, QKI-7, were uniquely
designed using Primer Express (Applied Biosystems, Fos-
ter City, USA), as described previously [2] (see Additional
file 2 for primer sequences). The expression data was col-
lected and analyzed with the ABI PRISM 7000 SDS soft-
ware (Applied Biosystems, Foster City, USA).
Statistical analysis
Messenger RNA expression levels of the QKI splice vari-
ants were normalized with the expression levels of the
endogenous control ACTB. In other words, our target var-
iable for the statistical analysis was the difference between
QKI and ACTB expression on a logarithmic scale. To test
the effect of antipsychotic treatment on QKI mRNA
expression, we analyzed each cell line separately with a
two-way ANOVA model, which included the factors treat-
ment, time and the interaction between treatment and
time. Comparisons between treated cells and their corre-
sponding controls were carried out with linear contrasts,
(i.e. with pre-planned t-test utilizing the pooled estimate
of error variance). The statistical analysis was carried out
in Proc GLM (SAS/STAT software, version 9.1.3, SAS insti-
tute Inc., Cary, NC).
Abbreviations
ACTB: actin beta; D2R: dopamine 2 receptor; D3R:
dopamine 3 receptor; FBS: fetal bovine serum; HOG:
human oligodendrogial cell line; PEST: penicillin-strepto-
mycin solution; PCR: polymerase chain reaction; QKI: The
quaking homolog, KH domain RNA binding (mouse); U343:
astrocytoma cell line.
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Additional file 1
Changes of QKI mRNA expression in U343 and HOG cells after treat-
ment with different antipsychotic drugs. The two upper tables show fold-
change of QKI expression, standard deviation and p-value for each treat-
ment in U343 and HOG cells. The lower table shows fold-changes of QKI 
expression, standard deviations and p-values after Haloperidol treatment, 
with the higher concentration (2 μM), of U343 cells. Changes with p-val-
ues < 0.05 are indicated with an asterisk. Two-fold differences are indi-
cated with a box.




Primer sequences used for detecting gene expression for ACTB, QKI-
5, QKI-6 and QKI-7. Primer sequences used to amplify ACTB-, QKI-5-
, QKI-6-, and QKI-7 mRNA.
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